Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000947871-13-000516
Filing Date
2013-07-16
Accepted
2013-07-16 21:52:04
Documents
1
Period of Report
2013-07-12

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT ss181939_3.html 3  
1 OWNERSHIP DOCUMENT ss181939_3.xml 3 8387
  Complete submission text file 0000947871-13-000516.txt   10863
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address
ISALY SAMUEL D (Reporting) CIK: 0001055949 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-35921 | Film No.: 13971398

Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-35921 | Film No.: 13971400

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6400
OrbiMed Capital GP IV LLC (Reporting) CIK: 0001502240 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-35921 | Film No.: 13971399

Mailing Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9363 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 (514) 337-3333
Mirati Therapeutics, Inc. (Issuer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations